miR-145 antisense oligonucleotide therapy (Ionis Pharmaceuticals/University of Alabama at Birmingham)

N/A

Report date: 2025/03/20 15:34:57
NME

Base Information

Drug NamemiR-145 antisense oligonucleotide therapy (Ionis Pharmaceuticals/University of Alabama at Birmingham)
Drug Alias Nameanti-miR-145 antisense oligonucleotides (University of Alabama at Birmingham/Ionis Pharmaceuticals)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisenseSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > microRNA
Mechanisms of ActionAntisense oligonucleotide inhibitors
TargetsUpdating
Therapy Area/IndicationsCystic Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Alabama At Birmingham
China Registration ClassN/A

Develop Information

Active CompaniesIonis Pharmaceuticals IncUniversity Of Alabama At Birmingham
Inactive CompaniesN/A
Active IndicationsCystic Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A